Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1:11:6003-6009.
doi: 10.2147/CMAR.S202546. eCollection 2019.

Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas

Yong Huang #  1 , Haixia Ding #  1 , Qiuji Wu  1 , Zhiqiang Li  2 , Huan Li  3 , Sirui Li  3 , Conghua Xie  1   4 , Yahua Zhong  1
Affiliations

Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas

Yong Huang et al. Cancer Manag Res. .

Abstract

Objective: Distinguishing recurrence and pseudoprogression is a major challenge in the clinical practice of treatment for high-grade gliomas (HGGs). The neutrophil-lymphocyte ratio (NLR) has been reported to be closely related to survival in HGGs. We aimed to assess the predictive value of NLR in the differential diagnosis of recurrence and pseudoprogression.

Materials and methods: A total of 135 patients with histologically confirmed HGGs were studied. All patients underwent focal radiotherapy and concomitant temozolomide (TMZ), followed by 6 cycles of TMZ if MRI showed no progressive enlargement of contrast-enhancing lesions. MRI evaluation was taken 4 weeks after concurrent chemoradiotherapy and then every 2 months later. NLR was calculated at 4 time points of preoperation, before concurrent RT-TMZ (pretreatment), 4 weeks following completion of RT-TMZ, and MRI showed lesion enlarged or treatment completed.

Results: In 135 patients, 47 (34.8%) were found to be pseudoprogression (PsPD), and 28 (20.7%) were early disease progression (ePD). The mean pretreatment and post-treatment NLR were 4.2±2.1 and 5.1±3.5, respectively. The median overall survival in the PsPD group (25.2 months) was significantly longer than in the ePD (15.4 months) and no progression group (nPD) (21.6 months) (p<0.001). Overall survival was significantly shorter in the baseline NLR≥4 cohort compared with NLR<4 (p=0.03), but no significant difference was found between PsPD and ePD (p=0.197). Patients with decreased NLR showed significantly longer survival than no decreased group (p<0.001), and decreased NLR was found to be a significant difference between PsPD and ePD (p=0.022). Univariate and multivariate logistic regression analyses suggested that decreased NLR was an independent prognosis factor (p=0.031).

Conclusion: Decreased NLR is an independent prognostic factor and is useful for distinguishing between recurrence and pseudoprogression in HGGs.

Keywords: high-grade gliomas; neutrophil–lymphocyte ratio; prognostic factors; pseudoprogression.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
MRI findings and outcomes of patients. Abbreviations: MRI, magnetic; resonance imaging; HCGs, high-grade gliomas; TMZ, temozolomide; RT-TMZ, radiotherapy Concurrent TMZ chemotherapy; PD, disease progression; PsPD, pseudoprogression; ePD, early disease progression; MDT, multidisciplinary team.
Figure 2
Figure 2
Overall survival for pseudoprogression, early disease progression and neither pseudoprogression nor early disease progression.
Figure 3
Figure 3
Overall survival for different baseline NLRs.
Figure 4
Figure 4
Overall survival for increased and no increased NLR. Abbreviation: NLR, neutrophil–lymphocyte ratio.
Figure 5
Figure 5
Overall survival for decreased and no decreased NLR. Abbreviation: NLR, neutrophil–lymphocyte ratio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15:ii1–ii56. doi:10.1093/neuonc/not151 - DOI - PMC - PubMed
    1. Alexander BM 1, Cloughesy TF. Adult glioblastoma. J Clin Oncol. 2017;35(21):2402–2409. doi:10.1200/JCO.2017.73.0119 - DOI - PubMed
    1. Linz U. Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (lancet oncol. 2009;10:459–466). Cancer. 2010;116(8):1844–1846. doi:10.1002/cncr.24950 - DOI - PubMed
    1. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. doi:10.1200/JCO.2009.26.3541 - DOI - PubMed
    1. Brandsma D, Stalpers L, Taal W, Sminia P, van Den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–461. doi:10.1016/S1470-2045(08)70125-6 - DOI - PubMed